From: Impact of High-Intensity-NIV on the heart in stable COPD: a randomised cross-over pilot study
Variable | Order | Baseline | LI-NIV | HI-NIV | Treatment effect HI vs. LI Mean (95% CI) | P |
---|---|---|---|---|---|---|
Change in CO, % of baseline | LIHI |  | −7.8 ± 14.9 | 3.2 ± 19.2 | −8.5% (−27 to 10%) | 0.33 |
 | HILI |  | 17.7 ± 34.6 | −10.3 ± 24.8 |  |  |
CO, L/min | LIHI | 5.8 ± 1.1 | 5.3 ± 1.1 | 5.9 ± 1.2 | −0.38 (−1.31 to 0.56) | 0.39 |
 | HILI | 5.1 ± 0.7 | 5.9 ± 1.1 | 4.5 ± 1.1 |  |  |
NTproBNP,pg/ml## | LIHI | 177 (117–317) | 113 (63–197) | 158 (67–208) | 37 (−26 to 101) | 0.22 |
 | HILI | 215 (61–469) | 199 (91–430) | 158 (88–620) |  |  |
PaCO2, day, kPa | LIHI | 6.7 ± 0.7 | 6.3 ± 0.7 | 6.1 ± 0.8* | −2.8 (−6.6 to 1.0) | 0.13 |
 | HILI | 7.0 ± 1.1 | 6.6 ± 0.7 | 6.0 ± 0.7* |  |  |
FEV1, L | LIHI | 0.72 ± 0.14 | 0.79 ± 0.20* | 0.75 ± 0.21* | −0.00 (−0.11 to 0.10) | 0.93 |
 | HILI | 0.95 ± 0.55 | 1.10 ± 0.63* | 1.13 ± 0.63* |  |  |
SRI-SS | LIHI | 43.3 ± 20.2 | 52.2 ± 19.7* | 49.8 ± 20.8* | −2.9 (−8.0 to 2.0) | 0.22 |
 | HILI | 45.2 ± 13.6 | 55.7 ± 8.4* | 52.6 ± 9.9* |  |  |